Hepatology (Baltimore, Md.)
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).
Zhi-Cheng Jin, Jingwei Wei, Yu-Dong Xiao, Anfeng Si, Jian-Jian Chen, Xiao-Li Zhu, Jin-Ze Li, Fang Nie, Rong Ding, Hai-Feng Zhou, Wei Ding, Bin-Yan Zhong, Yangyang Xie, Hong-Tao Hu, Guo-Wen Yin
Published: 202510.1097/HEP.0000000000001593
Abstract
BACKGROUND AND AIMS: This study aims to quantify intratumoral heterogeneity (ITH) and identify prognostic imaging biomarkers in patients with HCC treated with transarterial chemoembolization combined with immune checkpoint inhibitor plus molecular ta…
Preview only. Read the full abstract at the source